Brainstorm Cell Therapeut... (BCLI)
NASDAQ: BCLI
· Real-Time Price · USD
0.63
0.03 (5.00%)
At close: Aug 15, 2025, 3:47 PM
0.61
-2.38%
After-hours: Aug 15, 2025, 03:47 PM EDT
Brainstorm Cell Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -2.86M | -2.97M | -2.71M | -2.54M | -3.4M | -5.58M | -1.23M | -5.33M | -5.06M | -5.02M | -6.86M | -7.04M | -5.36M | -6.19M | -5.34M | -6.27M | -6.66M |
Depreciation & Amortization | 52K | 53K | 59K | 64K | 64K | 66K | 65K | 67K | 67K | 70K | 70K | 71K | 74K | 70K | 67K | 62K | 61K |
Stock-Based Compensation | 717K | 208K | 178K | 194K | 170K | -50K | 548K | 988K | 4K | 377K | 395K | 405K | 505K | 640K | 196K | 458K | 290K |
Other Working Capital | 416K | 469K | 154K | 228K | 250K | 6M | -116K | -130K | 3K | -95K | 17K | -592K | -100K | -989K | -1.64M | -318K | -114K |
Other Non-Cash Items | -179K | -282K | -394K | -411K | -3K | -759.05K | -4.76M | n/a | n/a | 646K | -34K | n/a | n/a | n/a | n/a | -115K | n/a |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -1.58M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 643K | 1.95M | -434K | 1.01M | 107K | 4.62M | -1.03M | -2.5M | 1M | -723K | 1.58M | 431K | 1.09M | -28K | -1.39M | 535K | -2.66M |
Operating Cash Flow | -1.63M | -1.05M | -3.3M | -1.68M | -3.06M | -3.29M | -6.41M | -6.78M | -3.99M | -4.65M | -4.85M | -6.13M | -3.69M | -5.51M | -6.46M | -5.33M | -8.97M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | -18K | n/a | n/a | 29K | -1K | -19K | -9K | -35K | -237K | -28K | -30K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | 196K | 6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | 12K | n/a | n/a | n/a | n/a | n/a | 4K | 2M | 1.01M | -10K | 7K | -8K | -1.26M | 1.93M | -11K | -7K |
Investing Cash Flow | n/a | 12K | n/a | n/a | n/a | 196K | -12K | 4K | 2M | 1.04M | -11K | -12K | -17K | -1.3M | 1.7M | -39K | -37K |
Debt Repayment | 900K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -106K | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 1.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Financial Cash Flow | 3.09M | 1.06M | n/a | 4.37M | 2.54M | 3.35M | 7.1M | 5.3M | 3.23M | 238K | n/a | n/a | n/a | -34K | -106K | n/a | 7.11M |
Net Cash Flow | 1.46M | 22K | -3.3M | 2.69M | -524K | 78K | 676K | -1.48M | 1.25M | -3.37M | -4.86M | -6.15M | -3.71M | -6.84M | -4.87M | -5.37M | -1.9M |
Free Cash Flow | -1.63M | -1.05M | -3.3M | -1.68M | -3.06M | -3.29M | -6.43M | -6.78M | -3.99M | -4.65M | -4.85M | -6.15M | -3.7M | -5.54M | -6.7M | -5.36M | -9M |